Actinium climbs on completing patient enrollment in cancer therapy study

Actinium Pharmaceuticals

15/09/2021 18:11

** Shares of cancer therapy developer  ATNM.A  rise 15.3% to
$6.64
    ** ATNM says it has completed enrollment in its key
late-stage trial testing its experimental therapy, Iomab-B, in
patients with relapsed or refractory acute myeloid leukemia - a
type of blood cancer  urn:newsml:reuters.com:*:nPn3wchkYa
    ** The trial will be conducted among 150 patients, aged 55
and above- co
    **  Expects to report topline data from the trial in
mid-2022, which could support the therapy's marketing
application
    ** Co had previously presented data showing lower rates of
serious adverse events in patients receiving Iomab-B vs other
treatments
    ** Stock down 14.9% YTD
    

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))